AACR Tumor Immunology and Immunotherapy Conference
AACR Tumor Immunology and Immunotherapy Conference November 27 - 30, 2018 | Loews Miami Beach Hotel, Miami Beach, Florida, USA Wednesday, Nov. 28 - Plenary Session 3: Metabolic Regulation in Tumors: Implications for Therapy Session Chair: Matthew G. Vander Heiden, David H. Koch Institute
Rgenix Treats First Patient in Phase 1 Trial of RGX-202
NEW YORK – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced it has treated the first patient in a Phase 1 a/b study of RGX-202, an oral small molecule being developed for the
Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs
Lepu Holdings Limited leads the financing syndicate and is joined by existing major investors Novo Holdings A/S and Sofinnova Partners New York, NY – October 9, 2018 — Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer
Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting
RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase Ia/b trial with a RGX-104 monotherapy expansion cohort and dose escalation/ expansion cohorts of RGX-104 in combination with nivolumab. New York,
Rgenix To Present Data on RGX-104 Clinical Activity at 2018 ASCO Annual Meeting
New York, NY – May 31, 2018 — Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it will present its abstract on RGX-104’s pharmacodynamic and clinical activity at the 2018